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Summary Vascular endothelial growth factor (VEGF) is a potent, multifunctional
cytokine that contributes to angiogenesis and inflammation. Matrix metalloprotei-
nase-9 (MMP-9) is one of the major proteolytic enzymes that degrade various
components of the extracellular matrix. Few data are available on the potential
relationship between VEGF and MMP-9 in the accumulation of pleural effusion. We
examined levels of VEGF and MMP-9 by means of enzyme immunoassay, zymographic
analysis, and Western blot analysis in the patients with liver cirrhosis, tuberculosis, or
lung cancer. The levels of VEGF and MMP-9 were significantly increased in the pleural
fluids and sera of patients with tuberculosis and were even higher in patients with
lung cancer compared with the patients with liver cirrhosis. A significant correlation
was established between the level of VEGF and the level of MMP-9 in the pleural
effusion. These results suggest that overproduction of VEGF and MMP-9 is associated
with accumulation of the pleural effusion in tuberculosis and lung cancer. The
relationship between VEGF and MMP-9 in the pleural effusion may have a role in the
pathogenesis of pleural fluid formation.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Pleural effusion is seen in patients with various
benign and malignant diseases such as liver
cirrhosis, tuberculosis, or lung cancer. However,
the basic mechanism by which fluid accumulates
within the pleural space is poorly understood.
Vascular endothelial growth factor (VEGF) is one
of the most potent proangiogenic cytokines and
exhibits mitotic activity specific for vascular
endothelial cells. VEGF also enhances a vascular
permeablilty and plays a critical role in tumor
progression probably due to its angiogenesis
action.1,2
Matrix metalloproteinases (MMPs) are proteolytic
enzymes involving in turnover of extracellular
matrix (ECM) proteins. These enzymes are known
to play an important role in pathologic conditions
such as tumor invasion.3,4 Of the MMP family, MMP-
9 may play a role in chronic inflammation. The
enzyme induces migration of inflammatory cells
such as eosinophils, neutrophils, and lymphocytes
across basement membrane. Furthermore, there is
evidence that VEGF stimulates MMP-9 secretion.5
However, few data are available on the potential
relationship between VEGF and MMP-9 in the
accumulation of pleural effusion.
In the present study, we evaluated whether the
VEGF and MMP-9 participate in the pathogenesis of
pleural fluid formation of patients with liver
cirrhosis, tuberculosis, or lung cancer. An additional
aim of the present study was to determine whether
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the level of VEGF in the pleural fluids of patients
with liver cirrhosis, tuberculosis, or lung cancer
correlated with the level of MMP-9.
Material and methods
Subjects
Fourty patients with lung cancer, 27 patients with
tuberculosis, and 16 patients with liver cirrhosis
were recruited from the Chonbuk National Uni-
versity Hospital. The pleural effusion was classified
as exudates or transudates according to the Light’s
criteria.6
Exudate (n ¼ 67): when the ratio of pleural fluid/
serum proteins is higher than 0.5, pleural fluid/
serum LDH40.6, or pleural fluid LDH42/3 of the
upper normal limit in serum LDH.
* Lung cancer (n ¼ 40): Diagnosis was established
by pleural fluid cytology in 12 patients and
histologic finding on a pleural biopsy specimen in
28 patients (19 with squamous cell carcinoma,
nine with small cell carcinoma, 12 with adeno-
carcinoma).
* Tuberculosis (n ¼ 27): Diagnosis was established
by sputum AFB stain or positive culture in 10
patients and typical histological characteristics
on a tissue biopsy specimen in 17 patients.
Transudate; liver cirrhosis (n ¼ 16): when the
ratio of pleural fluid/serum proteins is lower than
0.5, pleural fluid/serum LDHo0.6, and pleural fluid
LDHo2/3 of the upper normal limit in serum LDH.
Diagnosis was established when thrombocytopenia
and the reverse of albumin/globulin ratio in
laboratory findings, splenomegaly or hepatic shir-
inkage including irregularity of margin and ascite
formation in ultrasonography, and esophageal varix
in upper esophagogastric endoscopy were present.
This study was approved by the Ethics Committee
of Chonbuk National University, Medical School and
fully informed, written consent was obtained from
each subject.
Sample processing
Pleural effusion was collected via diagnostic thor-
acentesis. After centrifugation at 3000 rotations/
min for 20min at 41C, the cell-free supernatant was
separated and stored at 701C for subsequent VEGF
and MMP-9 measurement. Serum samples were
simultaneously collected and stored at 701C.
Cellular and biochemical analysis of pleural
effusion
At the time of the thoracentesis, pleural fluid was
collected in an ethylenediamine tetraacetic acid
tube for the measurement of the total and
differential WBC count, and in a plain tube for
glucose, protein, LDH, and adenosine deaminase
(ADA) analysis. WBC count was obtained by manu-
ally counting 100 cells on a smear stained with
Wright’s stain after the cells had been concen-
trated by cytocentrifugation at 2000 rotations/min
for 10min. Glucose, protein, and LDH concentra-
tions were measured using as automated analyzer
(Vitro Model 950; Johnson & Johnson: New York, NY,
USA). ADA activity was measured with a commer-
cial assay kit (Toyobo Co., Osaka, Japan).
Enzyme linked immunosorbent assay of VEGF
and MMP-9
The levels of VEGF were determined using a human
VEGF enzyme immunoassay kit (R&D Systems Inc.,
Minneapolis, MN, USA). The levels of MMP-9 were
quantified by enzyme immunoassays according to
the manufacturer’s protocol (Fuji Chemical Indus-
tries, Toyama, Japan). The minimum detectable
levels of VEGF and MMP-9 are 5.0 pg/ml and 1.2 ng/
ml, respectively.
Gelatin zymography of MMP-9
The hydrolytic activity of MMP-9 in pleural effusion
was measured by gelatin zymography. Zymography
was performed as previously desecribed.7 Briefly,
samples containing the same amount of protein
(10 mg) were mixed with 5 sample buffer (0.4M
Tris-HCl, pH 6.8, 5% SDS, 20% glycerol, 0.1%
bromophenol blue) and were separated by 10%
SDS-PAGE gels containing 0.1% gelatin. After elec-
trophoresis, the gels were incubated in 2.5% Triton
X-100 for 1 h and were then placed in the enzyme
buffer (0.05M Tris-HCl, pH 7.5, 0.02M NaCl, 5mM
CaCl2, and 0.02% Brij-35) for 24 h at 371C. The gels
were stained with 0.5% Coomassie brilliant blue-
250 solution and destained with several changes of
30% methanol and 10% acetic acid. Gelatinolytic
activity was detected as clear bands against a blue
background.
Western blot analysis of VEGF
Each pleural fluid supernatant was quantified using
the Bradford reagent (Bio-rad) and 3 mg of pleural
fluid protein was loaded on 12% SDS-PAGE gel and
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separated at 120 V for 90min. After electroporesis,
separated proteins were transferred to polyvinyli-
dene difluoride membranes (Amersham Pharmacia)
by the wet transfer method (250mA, 90min).
Nonspecific sites were blocked with 5% nonfat milk
in TBST buffer (25mM Tris pH 7.5, 150mM NaCl,
0.1% Tween 20) for 2 h and the anti-VEGF antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) diluted
1:500, was then incubated for 2 h in TBST buffer at
room temperature. Specific binding was visualized
using enhanced chemiluminescence system re-
agents (Amersham Pharmacia), and exposed to
photographic film.
Statistical analysis
All values are reported as means7SD unless other-
wise stated. The Kruskal–Wallis analysis of variance
test was used to examine significant intergroup
differences and if significant, the Mann–Whitney U
test was used for between-group comparisons.
Spearman’s rank correlation was calculated to
assess the correlation between data. Data were
considered statistically significant if p values were
less than 0.05. Statistical analysis was performed
using the SPSS 8.0 software (SPSS Inc., Chicago, IL,
USA).
Results
Characteristics of subjects and pleural
effusion
The mean ages of patients with lung cancer
(58.377.03), tuberculosis (49.178.57), and liver
cirrhosis (54.878.94) were comparable with each
other. The numbers of patients and sex ratio of lung
cancer (n ¼ 40; M=F ¼ 24=16), tuberculosis (n ¼ 27;
M=F ¼ 14=13), and liver cirrhosis (n ¼ 16;
M=F ¼ 10=6) were comparable with each other
(Table 1). Total WBC numbers and LDH levels in
the pleural fluids were significantly elevated in the
patients with lung cancer and tuberculosis as
compared to the patients with liver cirrhosis.
However, no significant difference in these levels
was observed between the lung cancer and the
tuberculosis patients. ADA levels in the pleural
fluids were significantly higher in the patients with
tuberculosis than the patients with lung cancer and
liver cirrhosis. The numbers of lymphocytes in the
pleural fluids of the patients with lung cancer and
tuberculosis were significantly increased as com-
pared to the patients with liver cirrhosis. However,
the numbers of lymphocyte were similar to the lung
cancer and the tuberculosis patients (Table 2). The
levels of VEGF in the pleural fluids were increased
approximately 14.5 fold in the patients with
tuberculosis and approximately 34.2 fold in the
patients with lung cancer as compared to those of
liver cirrhosis patients. The levels of MMP-9 in the
pleural fluids were also increased approximately
3.2 fold in the patients with tuberculosis and
approximately 6.9 fold in the patients with lung
cancer as compared to those of liver cirrhosis
patients (Table 2).
VEGF levels in pleural effusion
Enzyme immunoassay showed that the concentra-
tion of VEGF normalized to pleural fluid protein
content was significantly increased in the patients
with tuberculosis and were even higher in the
patients with lung cancer than those of the patients
with liver cirrhosis. The levels of VEGF in the
pleural fluids of patients with lung cancer were also
significantly elevated as compared to the patients
with tuberculosis (Fig. 1A). However, there was no
significant difference in VEGF levels in the pleural
fluids of patients with lung cancer of different
histological types. Consistent with the results
obtained from enzyme immunoassay, Western blot
analysis revealed that VEGF levels were increased
in the pleural fluids of patients with tuberculosis
and were even higher in the patients with lung
cancer compared with the patients with liver
cirrhosis. And, the levels of VEGF in the pleural
fluids of patients with lung cancer were higher than
the patients with tuberculosis (Fig. 1B).
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Table 1 Patients characteristics.
Transudate Exudate
Disease Liver cirrhosis Tuberculosis Lung cancer
Number 16 27 40
Age (yr) 54.878.94 49.178.57 58.377.03
Sex (M/F) 10/6 14/13 24/16
Data are presented as means7SD.
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MMP-9 levels in pleural effusion
Enzyme immunoassay showed that the concentra-
tion of MMP-9 normalized to pleural fluid protein
content was significantly elevated in the pleural
fluids of patients with tuberculosis and were even
higher in the patients with lung cancer than those of
the patients with liver cirrhosis. The levels of MMP-9
in the pleural fluids of the patients with lung cancer
were also significantly increased as compared to
those of the patients with tuberculosis (Fig. 2A).
However, there was no significant difference in MMP-
9 levels in the pleural fluids of patients with lung
cancer of different histological types. Consistent
with the results obtained from enzyme immunoas-
say, gelatin zymography revealed that the levels of
MMP-9 were also increased in the pleural fluids of
the patients with tuberculosis and were even higher
in the patients with lung cancer than the patients
with liver cirrhosis. The levels of MMP-9 in the
pleural fluids of patients with lung cancer were
higher than the patients with tuberculosis (Fig. 2B).
The correlation of VEGF with MMP-9 in
pleural effusion
In the pleural fluids of the patients with liver
cirrhosis, tuberculosis, or lung cancer, levels of
VEGF were significantly correlated with those of
MMP-9 (r ¼ 0:883; Po0:01) (Fig. 3).
The correlation of lymphocytes with the
levels of VEGF or MMP-9
In the pleural fluids of the patients with liver
cirrhosis, tuberculosis, and lung cancer, levels of
VEGF or MMP-9 were significantly correlated with
the number of lymphocytes (r ¼ 0:556; Po0:01 or
r ¼ 0:511; Po0:01; respectively) (Fig. 4).
Serum levels of VEGF and MMP-9
Enzyme immunoassay revealed that the levels of
vegf and mmp-9 were increased in the sera of
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Table 2 Characteistics of pleural effusions in different diseases.
Transudate Exudate
Disease Liver cirrhosis Tuberculosis Lung cancer
WBC (cells/ml) 263.2726 2437.171527.1* 2066.57681.8*
Lymphocyte (cells/ml) 228.8721.1 2217.87170.6* 1859.07165.3*
Protein (g/dl) 1.370.7 3.970.6* 3.771.2*
Glucose (mg/dl) 95.2723.9 98.1735.0 107.5735.0
LDH (IU/l) 121.1739.1 650.167273.1* 422.67177.7*
ADA (IU/l) 6.573.1 72.8728.7*w 7.675.1
VEGF (pg/ml) 75.8777.3 1100.57368.4*w 2595.77718.5*
MMP-9 (ng/ml) 33.0716.0 1.06.3730.1*w 226.6764.4*
*Po0:01 versus liver cirrhosis; wPo0:01 versus lung cancer.
LDH¼ lactate dehydrigenase(normal;o200 IU/l).
ADA¼ adenosine deaminase.
Data are presented as means7SD.
Figure 1 (A) The levels of VEGF in the pleural fluids of
patients of liver cirrhosis, tuberculosis, or lung cancer by
enzyme immunoassay; and (B) Western blot analysis of
VEGF in the pleural effusions of liver cirrhosis, tubercu-
losis, or lung cancer.
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patients with tuberculosis (989.47491.1 pg/ml and
397.67204.3 ng/ml) and were even higher in the
patients with lung cancer (1638.77617.1 pg/ml
and 949.87391.0 ng/ml) than those of the patients
with liver cirrhosis (413.47254.1 pg/ml and
97.6752.6 ng/ml). the levels of vegf and mmp-9
in the sera of patients with lung cancer
were significantly higher than the patients with
tuberculosis (Fig. 5).
Discussion
Abnormal accumulation of pleural fluid probably
occurs due to a combination of increased pleural
fluid formation and in some cases, decreased
lymphatic drainage.8,9 Increased permeability of
the capillaries in visceral pleura is considered to
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Figure 2 (A) The levels of MMP-9 in the pleural fluids of patients with liver cirrhosis, tuberculosis, or lung cancer by
enzyme immunoassay; and (B) gelatin zymography of pleural effusions of liver cirrhosis, tuberculosis, or lung cancer. A
representative zymographic analysis of pleural fluid supernatant samples obtained from liver cirrhosis (lanes 1,2),
tuberculosis (lanes 3,4), and lung cancer (lanes 5,6). Lanes S contains standards, the pro-form of MMP-2 (pMMP-2), the
active form of MMP-2 (aMMP-2), and the pro-form of MMP-9 (pMMP-9).
Figure 3 The correlation of the levels of VEGF with the
levels of MMP-9 in the pleural fluids of patients with liver
cirrhosis, tuberculosis, or lung cancer.
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play an important role in the production of
exudative pleural effusion.9,10 However, the mole-
cular mechanisms or pathogenesis in pleural fluid
accumulation are poorly understood and no single
mediator has so far been found to be important in
all types of exudative pleural effusion. Especially,
the origin of pleural effusion in malignancy is not
definitely known and the pathogenesis is probably
multifactorial.11
In our study, the levels of VEGF are high in the
pleural fluids of patients with tuberculosis and even
higher in the patients with lung cancer compared
with the patients with liver cirrhosis. We also
showed that the levels of VEGF were significantly
correlated with the number of lymphocytes in the
pleural fluids of patients with liver cirrhosis,
tuberculosis, and lung cancer. Increased pleural
permeability and local interaction of cells and
cytokines are associated with the pleural effusion
of tuberculosis caused by reactive response of
lymphocytes.12 VEGF is produced by most inflam-
matory cells including eosinophils, neutrophils,
macrophages, and lymphocytes.13 VEGF produced
by lymphocytes may be present in the pleural fluids
of patients with tuberculosis. VEGF is an endothe-
lial cell-specific potent, multifunctional cytokine
that plays an important role in vasculogenesis and
angiogenesis. Interestingly, formation of VEGF
mRNA is found in almost all tumors.1,14–16 The
contribution of VEGF to pleural fluid accumulation
through increment in vascular permeability has also
been reported in an animal model.17 Its ability to
increase vascular permeability and contribution to
tumor angiogenesis at the site of tumor progression
has been also observed.18 Yeo et al.19 showed that
significant amount of VEGF was present in malig-
nant pleural effusion associated with lung cancer,
and the VEGF present in the pleural fluid was
produced by the malignant cells as well as mono-
cytes, macrophages, or lymphocytes in the pleural
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Figure 4 (A) The correlation of the number of
lymphocytes and the levels of VEGF in the pleural
effusions of liver cirrhosis, tuberculosis or lung cancer;
and (B) the correlation of the number of lymphocytes
with the levels of MMP-9 in the pleural fluids of patients
of liver cirrhosis, tuberculosis, or lung cancer.
Figure 5 The levels of VEGF (A); and MMP-9 (B) in the
sera of patients of liver cirrhosis, tuberculosis or lung
cancer by enzyme immunoassay.
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fluids.10 In addition, it is possible that VEGF from
the tumor tissue enter the pleural space and could
increase the permeability of capillaries in the
pleura, leading to increase pleural fluid forma-
tion.15 Accordingly, VEGF can be detected in the
malignant pleural effusion with lung cancer. Taken
together, we suggest that the sources of VEGF may
be malignant cells as well as inflammatory cells
including lymphocytes and that VEGF may play a
crucial role in the pathogenesis of pleural effusion
of tuberculosis and lung cancer.
In our study, the levels of MMP-9 are high in the
pleural fluids of patients with tuberculosis and even
higher in the patients with lung cancer compared
with the patients with liver cirrhosis. The pleural
effusion of tuberculosis caused by reactive re-
sponse of lymphocytes is associated with increased
pleural permeability and local interaction of cells
and cytokines, which possibly contribute to MMP-9
accumulation.12 In this study, we showed the
correlation between the number of lymphocytes
and the levels of MMP-9 in the pleural fluids of
patients with liver cirrhosis, tuberculosis, and lung
cancer. MMP-9 produced by lymphocytes may be
present in the pleural fluids of patients with
tuberculosis. Inflammatory cells can produce
MMP-9, which might contribute to ECM degradation
and absorption in numerous pathophysiological
processes including infection and immunologically
mediated diseases.20,21 In addition to fibroblast,
endothelial cells, granulocyte, and macrophage,
tumor cells may also contribute to the production
of MMP-9 Proteolysis of basement membrane
gelatin/type-IV collagen by MMP-9 is considered
to be a crucial component of cancer invasion and
metastasis. Therefore, MMP-9 can be detected in
the malignant pleural effusion. This contributes to
formation of pleural effusion of inflammatory or
malignant diseases. Taken together, we suggest
that malignant cells may be partly involved in the
production of MMP-9 in addition to inflammatory
cells such as lymphocytes, and MMP-9 may play a
crucial role in the pathogenesis of pleural effusion
of tuberculosis or lung cancer.
In our study, a significant correlation was found
between the levels of VEGF and the levels of MMP-9
in the pleural fluids of patients with liver cirrhosis,
tuberculosis, or lung cancer. It is possible that
inflammatory cells and tumor cells are sources of
VEGF and MMP-9 and are involved in the formation
of pleural fluid. Previously, Wang et al.5 also
showed that VEGF enhances MMP-9 secretion from
human smooth muscle cells. Furthermore, the
presence of relatively high concentration of these
proteins in the pleural fluids of patients with lung
cancer suggests that they might serve as important
function in accumulation of pleural fluid of patients
with lung cancer.
Conclusively, we believe that, at least, VEGF and
MMP-9 are involved in the pathogenesis of pleural
effusion of patients with tuberculosis or lung
cancer in view of the increment and correlation
between them, especially malignant pleural effu-
sion caused by lung cancer. In addition to inflam-
matory cells such as lymphocytes, tumor cells may
be partly involved in the production of VEGF and
MMP-9. The clinical use of VEGF and MMP-9
measurement in the pleural effusion as a differ-
ential diagnostic parameter or diagnostic reference
may be possible with other parameters. However,
further studies are needed to determine the
clinical value of soluble VEGF and MMP-9 in
diagnostic and therapeutic aspects in pleural
effusion.
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